Antibiotic resistance (AR) poses a significant global threat, jeopardizing modern medicine's ability to treat bacterial infections.  While the clinical implications are widely understood, significant experimental challenges hinder effective countermeasures.  Investigating the complex interplay of resistance mechanisms, encompassing genetic mutations, horizontal gene transfer, and biofilm formation, proves difficult.  High-throughput screening of novel antibiotics is hampered by the limited availability of suitable drug targets and the inherent difficulty in predicting efficacy against diverse bacterial populations exhibiting varying resistance profiles.  Furthermore, the development of accurate and rapid diagnostic tools capable of identifying resistant strains remains a crucial unmet need.  In vivo studies are complex, requiring sophisticated animal models that accurately reflect human infection dynamics, including the intricate host-pathogen interactions that influence AR development.  Finally, the economic burden of developing and implementing effective AR countermeasures, alongside global inequities in access to diagnostic tools and treatment, present substantial barriers to progress.  Overcoming these experimental challenges necessitates interdisciplinary collaboration and innovative approaches to drug discovery, diagnostics, and infection control.